HeartBeam Ranked Second Globally in Portable ECG Innovation
HeartBeam has been recognized as a top global innovator in portable ECG technology, ranking second worldwide in 12-lead ECG innovation among 243 companies analyzed, highlighting the company's growing influence in remote cardiac care solutions.
HeartBeam has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report. The medical-technology company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare in the comprehensive evaluation. This recognition underscores HeartBeam's significant progress in developing advanced electrocardiogram solutions for remote cardiac care.
The company's high ranking reflects the rapid maturation of its proprietary synthesis-ECG system, which captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This technological approach allows physicians to obtain comprehensive cardiac data from portable devices, potentially transforming how cardiac conditions are detected and monitored outside traditional medical facilities. The full details of the recognition can be found in PatentVest's report at https://ibn.fm/ZuLCr.
HeartBeam's intellectual property foundation was cited as a major factor in its strong placement. The company holds over 20 issued patents related to technology enablement, providing a competitive advantage in the rapidly evolving field of remote cardiac monitoring. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while its 12-Lead ECG synthesis software remains under FDA review.
The HeartBeam System is designed as a portable non-invasive recorder that captures, stores, and transfers a patient's 3-Lead electrocardiogram acquired from five electrodes. The device is intended for use by adult patients in both clinical settings and at home, though it does not conduct cardiac analysis itself. Instead, it can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by healthcare professionals.
This recognition comes at a time when remote patient monitoring and portable medical devices are gaining increased importance in healthcare delivery. The ability to capture comprehensive cardiac data outside traditional medical facilities could significantly impact how cardiac conditions are managed, potentially enabling earlier detection of problems and more continuous monitoring of at-risk patients. Investors and industry observers can access the latest news and updates relating to HeartBeam through the company's newsroom at https://ibn.fm/BEAT.